ArticleFrontiers in endocrinology2026
Preliminary lipidomics and transcriptomics reveals stage-specific dynamic metabolic patterns from menopause transition to postmenopause.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to systematically analyze the clinical indicators, lipid metabolism, and leukocyte transcriptomic profiles of premenopausal, menopause transition, and postmenopausal women. It sought to explore stage-specific characteristics of lipid metabolism and gene expression and their potential associations with key clinical indicators. Methods: Clinical indicators were collected, and untargeted lipidomics and leukocyte transcriptomic sequencing were performed. Multivariate statistical analyses were used to assess intergroup differences. Significant patterns in lipid and gene expression changes were identified through trend clustering, volcano plots, and Venn diagram analyses. GO and KEGG enrichment analyses were conducted to investigate the biological functions and pathway enrichment of differentially expressed genes. Results: With advancing menopausal stages, E2 levels were lower, while FSH and LH levels were higher. BMI was higher during the menopause transition and subsequently declined, whereas CHOL and LDLC levels were higher in both the menopause transition and postmenopause stages.Specific lipid classes showed partial return to baseline or further regulation in postmenopause. Transcriptomic analysis identified stage-specific differentially expressed genes enriched in inflammation- and lipid metabolism-related pathways. E2 was positively correlated with lipid molecules and marker genes, but negatively correlated with CHOL. Conclusion: This preliminary study indicates that menopausal stages are associated with significant stage-specific differences in lipid metabolism and gene expression, with the menopause transition identified as a critical phase of lipid metabolic reorganization. Certain lipids and genes may serve as potential biomarkers for menopause-associated metabolic differences. These findings provide important insights for early warning and intervention strategies targeting menopause-related health issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.